Elite Pharmaceuticals Strengthens Position in Market

One of the better articles written about $ELTP in recent years, this is the promise, and this is why longs have so much to look forward to.  Daily traders of the stock are quick to, but it's the long-term correlation of pharma + revenue and stock value that investors take confidence.

Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market

Jan. 29, 2015 8:06 AM ET  |  About: Elite Pharmaceuticals, Inc. (ELTP), Includes: ACT, ACUR, EGLT, PFE

Summary

• Elite Pharmaceuticals is poised to address a sizeable share of abuse deterrent opioid market.
• Drug trials continue to deliver the expected positive results.
• Continued growth and expansion of generic and other drug business.
• Significant leadership additions made to take the company to critical mass.

The past year for Elite Pharmaceuticals (OTCQB:ELTP) has been quite remarkable. While the stock price has taken investors on a bit of a roller coaster ride, the company's business trajectory has been exceptional. In the past year, we have seen numerous drug trials performed with outstanding results. We have seen the concerns previously associated with the company removed. Internally, the company has rapidly grown. Financials have not been stronger in many years. The future has never been brighter.
The truth is that Elite Pharmaceuticals is poised to make a play for a significant and diverse share of the entire $7 billion U.S. opioid market. Globally, the pain med market is $50 billion. To quote Peter Lynch:

Often, there is no correlation between the success of a company's operations and the success of its stock over a few months or even a few years. In the long term, there is a 100 percent correlation between the success of the company and the success of its stock. This disparity is the key to making money; it pays to be patient, and to own successful companies.

 READ MORE (must have Seeking Alpha account to continue reading article.)